ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
Multi-year collaboration will use ViaNautis’ non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell types.
ViaNautis Appoints Ray Jupp as Chief Scientific Officer
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic therapies, today announces the appointment of Dr Ray Jupp as…
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as…
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Steven M. Altschuler…
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
– ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet…